Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis?
Biancone
L
L
Petruzziello
C
C
Calabrese
E
E
Zorzi
F
F
Naccarato
P
P
Onali
S
S
Pallone
F
F
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000517:prevention & control*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab